SCHEMBL4846818

SCHEMBL4846818

Oc1cc(C=Cc2ccccn2)n(-c2ccccc2)n1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ATM Q13315 1/20 0.47
APP P05067 2/20 0.46
CAMK2A Q9UQM7 1/20 0.46
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
POLB P06746 2/20 0.39
TDP1 Q9NUW8 1/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
GRM4 Q14833 1/20 0.36
HSP90AA1 P07900 1/20 0.36
GRM5 P41594 1/20 0.35
SNCA P37840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4846810 1.00 NPC1 (0.47) NPC1RAB9AMEN1KMT2AATM
SCHEMBL4850941 0.78 KDM4C (0.49) KMT2AATMAPPCAMK2APTGS2
SCHEMBL10715419 0.69 MAPK1 (0.42) NPC1RAB9AKMT2ATDP1MAPT
Methyl Alcohol SCHEMBL28478479 0.69 NPC1 (0.89) NPC1RAB9AMEN1KMT2AATM
SCHEMBL9394256 0.69 NPC1 (1.00) NPC1RAB9AMEN1KMT2AATM
SCHEMBL229328 0.69 NPC1 (1.00) NPC1RAB9AMEN1KMT2AATM
SCHEMBL31560044 0.69 NPC1 (1.00) NPC1RAB9AMEN1KMT2AATM
SCHEMBL229329 0.69 NPC1 (1.00) NPC1RAB9AMEN1KMT2AATM
SCHEMBL4850432 0.67 HRH3 (0.41) MEN1KMT2ATDP1MAPTKDM4E
Resorcinol SCHEMBL38658629 0.67 NPC1 (0.67) NPC1RAB9AMEN1KMT2AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 NPC1 822/4885RAB9A 1036/4885MEN1 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.